In a report issued on December 10, Tobias Gottschalt from Independent Research maintained a Sell rating on Qiagen, with a price target of EUR36.00. The company’s shares closed last Friday at $51.92, close to its 52-week high of $55.27.
According to TipRanks.com, Gottschalt is ranked #5992 out of 7141 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Qiagen with a $57.13 average price target.
Roche Holding AG (RHHVF)
In a report issued on December 10, David Evans from Kepler Capital maintained a Hold rating on Roche Holding AG, with a price target of CHF299.00. The company’s shares closed last Friday at $343.00.
According to TipRanks.com, Evans is a 4-star analyst with an average return of 10.7% and a 73.6% success rate. Evans covers the Healthcare sector, focusing on stocks such as Innate Pharma, Crossject SA, and Pharnext SA.
Currently, the analyst consensus on Roche Holding AG is a Moderate Buy with an average price target of $417.84.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.